-
Innovation Ranking
NewInnovation Ranking – Daan Gene Co Ltd
Daan Gene Co Ltd (Daan Gene) is a provider of molecular diagnostic solutions. The company develops and produces in-vitro diagnostic products. It offers products such as real-time PCR products, gene sequencing machines, real-time PCR instruments, nucleic acid extraction instruments, reverse dot blot products, fish products, immunoassay products and rapid test products. Daan Gene’s products also include food safety products, blood collection tubes, and reference material and control material. It also offers biotechnology transfer services and biotechnology consulting and exchange services....
-
Innovation Ranking
NewInnovation Ranking – Sio Gene Therapies Inc
Sio Gene Therapies Inc (Sio Gene) is a clinical-stage biopharmaceutical company that develops and commercializes novel medicines. The company develops medicines for the treatment of multiple forms of dementia and related neurological disorders. Sio Gene's pipeline products comprise AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2. The company’s AXO-Lenti-PD is a lentiviral gene therapy that contains three genes that encode the critical enzymes required for endogenous dopamine synthesis. It develops gene therapies for GM1 and GM2 gangliosidosis including Tay-Sachs disease and Sandhoff disease. The...
-
Track & Monitor
NewCell & gene therapy in pharma: corneal endothelial cell culturing
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s corneal endothelial cell culturing within Cell & gene therapy innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned...
-
Product Insights
NewNet Present Value Model: Taysha Gene Therapies Inc’s TSHA-102
Empower your strategies with our Net Present Value Model: Taysha Gene Therapies Inc's TSHA-102 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy 2 For Oncology in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 2 For Oncology in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy 2 For Oncology in Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy 2 For Oncology in Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 2 For Oncology in Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy 2 For Oncology in Leukemia Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target GD2 For Oncology in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target GD2 For Oncology in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target GD2 For Oncology...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target GD2 For Oncology in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target GD2 For Oncology in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target GD2 For Oncology...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target GD2 For Neuroblastoma in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target GD2 For Neuroblastoma in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target GD2 For Neuroblastoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target GD2 For Oncology in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target GD2 For Oncology in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target GD2 For Oncology...